Compare AbbVie Inc (ABBV) vs ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs ProShares UltraShort Bloomberg Natural Gas ETF — how do they compare? AbbVie Inc trades at $249.02 (market cap $438.19B), while ProShares UltraShort Bloomberg Natural Gas ETF trades at $29.08. The key difference: AbbVie Inc pays a 2.79% dividend while ProShares UltraShort Bloomberg Natural Gas ETF pays none, and AbbVie Inc is trading nearer its 52-week high, ProShares UltraShort Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | KOLD | |
|---|---|---|
Market Cap | $438.19B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $263.58 | $49.39 |
52-Week Low | $197.38 | $13.58 |
Enterprise Value | $502.45B | — |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABBV trades at $249.94, up 1.59% today, with a bullish technical signal and strong analyst consensus. Recent earnings beats (Q4 2025 to Q2 2026) and a 70.73% buy rating from analysts highlight confidence. Revenue grew to $61.16B in 2025, though net margin dipped to 6.9%, while Skyrizi and Rinvoq drive growth post-Humira patent expiry. A dividend of $1.73 is scheduled for August 2026, supporting income appeal.
Outlook is positive with a $281.33 price target, but risks include high P/E of 70.05, patent cliffs in the 2030s, and regulatory lawsuits. Institutional buying and robust pipeline innovations like ELAHERE® in ovarian cancer offer upside, yet valuation and competitive pressures warrant caution for growth sustainability.
KOLD, trading at $31.22, is down 2.19% over the past 24 hours. The technical outlook is bullish based on moving averages, with key support at $30 and resistance at $32. Recent news highlights natural gas market volatility, with futures influenced by weather forecasts and LNG export flows. Financial ratios are unavailable in the provided data, limiting fundamental assessment.
The stock's near-term trajectory hinges on natural gas price movements and demand shifts. While technical indicators suggest upward momentum, the lack of fundamental data and exposure to commodity price swings present risks. Investors should weigh the ETF's leveraged structure against market volatility for tactical positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →
